Control | Telemedicine | OR* (control group data were reference values) | 95% CI for the OR | p Value | ||||
---|---|---|---|---|---|---|---|---|

Baseline N (%) (N=70) | Follow-up N (%) (N=64) | Baseline N (%) (N=69) | Follow-up N(%) (N=64) | Lower | Upper | |||

Snoring | 65 (96) | 12 (19) | 68 (100) | 14 (22) | 1.13 | 0.46 | 2.78 | 0.78 |

Witnessed apnoeas | 62 (97) | 12 (19) | 56 (88) | 12 (19) | 1.08 | 0.43 | 2.71 | 0.88 |

Daytime fatigue | 48 (69) | 14 (22) | 49 (71) | 21 (33) | 1.85 | 0.82 | 4.20 | 0.14 |

Nocturia | 39 (56) | 17 (27) | 44 (64) | 15 (23) | 0.74 | 0.31 | 1.74 | 0.48 |

Drowsy driving | 42 (60) | 15 (23) | 39 (57) | 12 (19) | 0.82 | 0.33 | 2.01 | 0.66 |

*Estimate of the OR comparing telemedicine versus standard (standard being the reference group) follow-up derived using the logistic regression model for the typical OSA symptom variables as response and with treatment group as a factor along with baseline typical OSA symptom variables as covariates.

OSA, obstructive sleep apnoea.